Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
24,141,356
-
Shares change
-
-796,169
-
Total reported value, excl. options
-
$42,026,786
-
Value change
-
-$4,185,117
-
Put/Call ratio
-
170%
-
Number of buys
-
35
-
Number of sells
-
-42
-
Price
-
$1.70
Significant Holders of BELLICUM PHARMACEUTICALS INC - COM (BLCM) as of Q2 2019
97 filings reported holding BLCM - BELLICUM PHARMACEUTICALS INC - COM as of Q2 2019.
BELLICUM PHARMACEUTICALS INC - COM (BLCM) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24,141,356 shares
.
Largest 10 shareholders include JPMORGAN CHASE & CO (3,381,146 shares), BAKER BROS. ADVISORS LP (2,677,818 shares), Nikko Asset Management Americas, Inc. (2,105,649 shares), Sumitomo Mitsui Trust Holdings, Inc. (2,105,649 shares), VANGUARD GROUP INC (1,877,331 shares), RENAISSANCE TECHNOLOGIES LLC (1,564,959 shares), ARK Investment Management LLC (1,284,955 shares), BlackRock Inc. (1,265,663 shares), FRAZIER MANAGEMENT LLC (1,051,441 shares), and GOLDMAN SACHS GROUP INC (672,633 shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.